The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Much has been said of Strive, perhaps we're in their thoughts, perhaps not.
Maybe there's another iron in the fire.
I think all this statement tells us is that when there's not much to say probably best to say nothing.
They obviously can't say "we are close to being on a trial" in an NY message
With February around the corner there will likely be some clarity on the intentions of Polygon so that's something to look forward to.
I don’t see why you continue to waste your time telling us that management have screwed up/ we failed a trial. This is known and priced in. Getting a new guy with a beard surely has no bearing on the decisions of NIH !
https://www.roche.com/innovation/partnering/pharma-jpm
Hopefully Jean-Eric was on Richards sailing trip ;-)
The picture has a syringe and a blister of tablets (palm face)
The glass vial behind I guess represents SNG, is this the blow glass fill process (?) which was spoken about some time ago?
Has there been any snippets on whether this has been adopted?
Did anyone else see that China have tapped up Shinogi for their treatment in trial, Ensitrelvir (maybe this is old news)
https://www.shionogi.com/global/en/news/2022/12/e20221229.html
If you're going to use the Specsavers line you should at least check they have 'cyber Monday' deals. ;-)
I followed the logic of having these bids in place to prop up the sp but don't follow why they would add another ~200k